Evidence map›Paper›PMID 27228256›Full record

ArticleJAMA oncology2016

Breast Cancer Risk From Modifiable and Nonmodifiable Risk Factors Among White Women in the United States.

Paige Maas, Myrto Barrdahl, Amit D Joshi, Paul L Auer, Mia M Gaudet, Roger L Milne, Fredrick R Schumacher, William F Anderson, David Check, Subham Chattopadhyay and 35 more

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in JAMA oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 212 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
212citing papers in PubMed, 13 pooled it
18.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

212 citing papers in PubMed, 13 syntheses or guidelines pooled it, 401 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. The Promise of Polygenic Risk Prediction in Smoking Cessation: Evidence From Two Treatment Trials.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2022
    Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Article
  17. Breast cancer polygenic risk score performance varies by socioeconomic status.medRxiv : the preprint server for health sciences · 2026
    Article
  18. Article
  19. Article
  20. Article

152 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

45 authors at 20 institutions in 8 countries.

Paige MaasDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Myrto BarrdahlDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Amit D JoshiProgram in Genetic Epidemiology and Statistical Genetics, Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
Paul L AuerFred Hutchinson Cancer Research Center, Seattle, Washington5School of Public Health, University of Wisconsin-Milwaukee, Milwaukee.
Mia M GaudetEpidemiology Research Program, American Cancer Society, Atlanta Georgia.
Roger L MilneCancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Australia8Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Victoria, Australia.
Fredrick R SchumacherDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles.
William F AndersonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
David CheckDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Subham ChattopadhyayDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Laura BagliettoCancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Australia8Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Victoria, Australia.
Christine D BergDivision of Cancer Prevention, National Cancer Institute, Bethesda, Maryland.
Stephen J ChanockDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
David G CoxINSERM U1052 - Cancer Research Center of Lyon, Centre Léon Bérard, Lyon, France12Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, England.
Jonine D FigueroaDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Mitchell H GailDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Barry I GraubardDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Christopher A HaimanDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles.
Susan E HankinsonDepartment of Biostatistics and Epidemiology, School of Public Health and Health Sciences, University of Massachusetts, Amherst14Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Robert N HooverDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Claudine IsaacsLombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.
Laurence N KolonelEpidemiology Program, Cancer Research Center, University of Hawaii, Honolulu.
Loic Le MarchandUniversity of Hawaii Cancer Center, Honolulu.
I-Min LeeDivision of Preventive Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Sara LindströmProgram in Genetic Epidemiology and Statistical Genetics, Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
Kim OvervadDepartment of Public Health, Aarhus University, Aarhus, Denmark.
Isabelle RomieuNutrition and Metabolism Section, International Agency for Research on Cancer, Lyon, France.
Maria-Jose SanchezEscuela Andaluza de Salud Pública. Instituto de Investigación Biosanitaria ibs.GRANADA. Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain22CIBER de Epidemiología y Salud Pública (CIBERESP), Spain.
Melissa C SoutheyGenetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, Melbourne, Australia.
Daniel O StramDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles.
Rosario TuminoCancer Registry and Histopathology Unit, "Civic- M.P.Arezzo" Hospital, ASP Ragusa, Italy.
Tyler J VanderWeeleDepartment of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts26Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
Walter C WillettDepartment of Nutrition, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
Shumin ZhangDivision of Preventive Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Julie E BuringDivision of Preventive Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Federico CanzianGerman Cancer Research Center (DKFZ), Heidelberg, Germany.
Susan M GapsturEpidemiology Research Program, American Cancer Society, Atlanta Georgia.
Brian E HendersonDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles.
David J HunterProgram in Genetic Epidemiology and Statistical Genetics, Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
Graham G GilesCancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Australia8Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Victoria, Australia29Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Ross L PrenticeFred Hutchinson Cancer Research Center, Seattle, Washington30University of Washington, School of Public Health and Community Medicine, Seattle.
Regina G ZieglerDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Peter KraftProgram in Genetic Epidemiology and Statistical Genetics, Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
Montse Garcia-ClosasDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland31Breakthrough Breast Cancer Research Centre, Division of Genetics and Epidemiology, The Institute of Cancer Research, London, England.
Nilanjan ChatterjeeDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland32Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland33Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, Maryland.
National Cancer Institute · USHarvard University · USNational Institutes of Health · USUniversity of Southern California · USAmerican Cancer Society · USBrigham and Women's Hospital · USUniversity of Melbourne · AUAarhus University · DKAzienda Usl 8 Arezzo · ITCancer Council Victoria · AUCentre de Recherche en Cancérologie de Lyon · FRCentre International de Recherche sur le Cancer · FRCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública · ESGeorgetown University · USGerman Cancer Research Center · DEHeidelberg University · DEMonash University · AUUniversity of Hawaiʻi at Mānoa · USUniversity of Hawaii Cancer CenterUniversity of Washington · US

Funding

Methods for Epidemiology StudiesZIACP010181 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI ALBERT, PAUL · 2009 to 2025
$34.8M
Characterizing Genetic Susceptibility to Breast and Prostate Cancer; the BPC3U01CA098758 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HENDERSON, BRIAN E · 2003 to 2010
$11.0M
Statistical Methods for Analysis of Massive Genetic and Genomic Data in Cancer ResearchR35CA197449 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI XIHONG LIN · 2015 to 2026
$10.9M
Characterizing Genetic Susceptibility to Breast and Prostate Cancer; the BPC3U01CA098233 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI HUNTER, DAVID JOHN · 2003 to 2010
$10.8M
Characterizing Genetic Susceptibility to Breast and Prostate Cancer; the BPC3U01CA098216 · NCI · INTERNATIONAL AGENCY FOR RES ON CANCER · PI RIBOLI, ELIO · 2003 to 2011
$7.4M
Methods for Epidemiology StudiesZ01CP010181 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI CHATTERJEE, NILANJAN · 2003 to 2008
$4.8M
Characterizing Genetic Susceptibility to Breast and Prostate Cancer: The BPC3.U01CA098710 · NCI · AMERICAN CANCER SOCIETY, INC. · PI GAPSTUR, SUSAN M · 2003 to 2011
$4.2M
Intramural NIH HHS Z01 CP010181NCI NIH HHS R35 CA197449NCI NIH HHS U01 CA098216NCI NIH HHS U01 CA098233NCI NIH HHS U01 CA098710NCI NIH HHS U01 CA098758NHLBI NIH HHS HHSN268201100001INHLBI NIH HHS HHSN268201100002INHLBI NIH HHS HHSN268201100003INHLBI NIH HHS HHSN268201100004INHLBI NIH HHS HHSN268201100046CNIA NIH HHS HHSN271201100004CWHI NIH HHS HHSN268201100001CWHI NIH HHS HHSN268201100002CWHI NIH HHS HHSN268201100003CWHI NIH HHS HHSN268201100004CWorld Health Organization 001
6 · The paper itself

Abstract

importanceAn improved model for risk stratification can be useful for guiding public health strategies of breast cancer prevention.

objectiveTo evaluate combined risk stratification utility of common low penetrant single nucleotide polymorphisms (SNPs) and epidemiologic risk factors. DESIGN, SETTING, AND

participantsUsing a total of 17 171 cases and 19 862 controls sampled from the Breast and Prostate Cancer Cohort Consortium (BPC3) and 5879 women participating in the 2010 National Health Interview Survey, a model for predicting absolute risk of breast cancer was developed combining information on individual level data on epidemiologic risk factors and 24 genotyped SNPs from prospective cohort studies, published estimate of odds ratios for 68 additional SNPs, population incidence rate from the National Cancer Institute-Surveillance, Epidemiology, and End Results Program cancer registry and data on risk factor distribution from nationally representative health survey. The model is used to project the distribution of absolute risk for the population of white women in the United States after adjustment for competing cause of mortality. EXPOSURES: Single nucleotide polymorphisms, family history, anthropometric factors, menstrual and/or reproductive factors, and lifestyle factors. MAIN OUTCOMES AND MEASURES: Degree of stratification of absolute risk owing to nonmodifiable (SNPs, family history, height, and some components of menstrual and/or reproductive history) and modifiable factors (body mass index [BMI; calculated as weight in kilograms divided by height in meters squared], menopausal hormone therapy [MHT], alcohol, and smoking).

resultsThe average absolute risk for a 30-year-old white woman in the United States developing invasive breast cancer by age 80 years is 11.3%. A model that includes all risk factors provided a range of average absolute risk from 4.4% to 23.5% for women in the bottom and top deciles of the risk distribution, respectively. For women who were at the lowest and highest deciles of nonmodifiable risks, the 5th and 95th percentile range of the risk distribution associated with 4 modifiable factors was 2.9% to 5.0% and 15.5% to 25.0%, respectively. For women in the highest decile of risk owing to nonmodifiable factors, those who had low BMI, did not drink or smoke, and did not use MHT had risks comparable to an average woman in the general population. CONCLUSIONS AND RELEVANCE: This model for absolute risk of breast cancer including SNPs can provide stratification for the population of white women in the United States. The model can also identify subsets of the population at an elevated risk that would benefit most from risk-reduction strategies based on altering modifiable factors. The effectiveness of this model for individual risk communication needs further investigation.

Indexed as

AdultAgedAged, 80 and overBreast NeoplasmsCase-Control StudiesFemaleGenetic Association StudiesGenetic Predisposition to DiseaseHumansMiddle AgedPolymorphism, Single NucleotideProspective StudiesRisk FactorsRisk Reduction BehaviorUnited StatesWhite People

Identifiers

PMID27228256
PMCPMC5719876
OpenAlexW2400613861

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.